Fingerprint
Dive into the research topics of 'Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials
Philip J. Rosenfeld, Howard Shapiro, Lisa Tuomi, Mary Webster, Julee Elledge, Barbara Blodi
Research output: Contribution to journal › Article › peer-review
208
Scopus
citations